KBI Biopharma, Inc. is a contract development and manufacturing organization (CDMO) that specializes in providing services for the development and production of biologic therapeutics. Its core activities include cell line development, upstream and downstream process development, analytical method development and characterization, as well as current good manufacturing practice (cGMP) production of monoclonal antibodies, recombinant proteins, and other complex biologics.
The company operates primarily in the United States with facilities dedicated to supporting pharmaceutical and biotechnology clients throughout the drug development lifecycle. It focuses on delivering scalable manufacturing solutions while maintaining high standards of quality and regulatory compliance required for clinical and commercial supply.
Founded in 1996, KBI Biopharma was acquired by JSR Corporation in 2015 and integrated into the JSR group as an affiliate. According to recent corporate announcements, it is transitioning to become a specified subsidiary of Mitsui Chemicals following a share purchase transaction involving JSR. This positions the company within the broader life sciences and materials sector while continuing its role as a specialized service provider in the global biopharmaceutical supply chain.
In the competitive CDMO industry, KBI Biopharma serves as a key partner for companies seeking expertise in biologic process optimization and manufacturing, contributing to the advancement of innovative therapies without engaging in its own drug discovery or marketing activities.
Also known as KBI.
None yet. When a new project in the record names KBI Biopharma as owner, partner or investor, it shows here.
Plans to buy JSR for ¥1.84 trillion, target closing in H2 of FY ending March 2028; DBJ to co-invest ¥200bn; shelf registration up to ¥150bn to help refinance a ¥1,640bn bridge loan.
